Sign in to fuzzto save your conversations, follow your research and come back anytime.
Viyash Scientific
SectorHealthcare
The Quarter story
The two most recent quarterly results, compared side-by-side.
Viyash Scientific scales revenue and profitability while managing rising operational costs and margin pressure.
EBITDA margin expands from 16.2% in Q1 FY26 to 21.6% in Q1 FY27, sustaining operational efficiency.
Gross profit margin slips from 61.1% in Q2 FY26 to 54.1% in Q1 FY27, showing pricing pressure.
Reported sales revenue grows from ₹4,240 Cr in Q2 FY26 to ₹9,464 Cr in Q1 FY27, confirming strong top-line expansion.
Operating expenses widen from ₹1,369 Cr in Q1 FY26 to ₹1,696 Cr in Q1 FY27, reflecting scaling overheads.
Customer audits rise from 34 in Q1 FY26 to 66 in Q1 FY27, reflecting growing client trust.
Material consumption costs deepen from ₹1,480 Cr in Q1 FY26 to ₹4,343 Cr in Q1 FY27, indicating higher production input costs.
R&D pipeline products jump from 16 in Q2 FY26 to 190 in Q1 FY27, signaling aggressive future growth.
Employee benefit expenses rise from ₹677 Cr in Q1 FY26 to ₹1,381 Cr in Q1 FY27, signaling workforce expansion costs.
Net debt to LTM EBITDA falls from 0.6x in Q1 FY26 to 0.1x in Q1 FY27, confirming a strong balance sheet.
API regulatory approvals fluctuate from 5 in Q1 FY26 to 3 in Q1 FY27, indicating uneven compliance pacing.